Effects of Labetalol on Nicotine Administration in Humans - 14

Completed · Phase 2

Conditions studied: Tobacco Use Disorder

In brief

The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine

Key facts

Study ID

NCT00000297

Run by

National Institute on Drug Abuse (NIDA)

People needed

0

Starts

1998-10-01

Expected to finish

2001-12-01

Last updated by the study team

2017-01-12

Who can join

Age: 21 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male/Female, aged 21-55 years with a smoking history of at least 1 pack of cigarettes daily for at least 1 year. In good health as verified by medical history, screening examination, and screening laboratory tests.

You may not qualify if…

• History of heart disease, peripheral vascular disease, COPD, any other medical condition which physician investigator deems inappropriate for subject participation. Pregnant or lactating or not using adequate birth control methods. Use of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics and recent psychiatric history). Chronic use of systemic steroids or antihistamines. Abuse of alcohol or any other recreational or prescription drug. Regular use of any other tobacco products, including smokeless tobacco and nicotine products.

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.